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nmol/L, P  0.001) to an undetectable expression (PMA 200Abnormalities of Gq-mediated cell signaling in Bartter and
nmol/L). Qualitatively similar effects were seen in monocytesGitelman syndromes.
from control subjects. Incubation of monocytes from patientsBackground. The constitutive endothelial isoform of nitric
and controls with the PKC inhibitor GF109203X increasedoxide synthase (ecNOS) and nitric oxide (NO) production are
ecNOS mRNA, with no difference between patients and con-increased in patients with Bartter syndrome (BS) and Gitelman
trols. Gq mRNA was reduced in BS/GS versus controls (0.87(GS) syndrome and may reduce vascular tone. Moreover, these
0.013 vs. 0.98  0.005 densitometric units, P  0.0004).patients present an abnormal cell signaling [reduced stimulated
Conclusion. An abnormal Gq expression blunts cell signal-intracellular calcium ([Ca2]i) and inositol-1,4,5,triphosphate
ing and PKC production in BS/GS. A reduced PKC up-regu-([IP3]i) in neutrophils], suggesting the presence of a generalized
lated NO system may contribute to the vascular hyporeactivityreduction of protein kinase C (PKC) and cell reactivity. Since
PKC regulates ecNOS gene expression, we evaluated the signal of BS/GS.
transduction system involving Gq protein, PKC, and ecNOS
in circulating nucleated cells from patients with BS/GS.
Methods. Nucleated blood cells from 2 BS and 7 GS and
Bartter syndrome (BS) and its variant Gitelman syn-from 10 controls (C) were used. PKC activity was evaluated
drome (GS) are characterized by genetic nonconserva-in neutrophils by radioenzymatic assay; PKC concentration
was evaluated in monocytes by Western blot analysis. ecNOS tive mutations in cotransporters and ion channels [1–4],
and Gq mRNA production was evaluated in monocytes by re- which account for some of their clinical findings such as
verse transcription-polymerase chain reaction (RT-PCR) anal- hyperreninemia, high plasma angiotensin II (Ang II), andysis using specific primers and quantitated by PCR-based semi-
hyperaldosteronism [5]. In addition, they present normo-quantitative analysis of ecNOS and Gq mRNA expression.
Results. Cytosol and membrane basal PKC activity were tension/hypotension, reduced total peripheral resistance,
similar in neutrophils from BS/GS and C (70  3 vs. 80  2; hyporesponsiveness to the pressor action of Ang II, and
37  3 vs. 46  2 pmol/min/mg protein, respectively), while norepinephrine [6], which are still matters of research.
fMLP-stimulated membrane PKC activity increased to a lower
We have demonstrated that patients with BS andextent in BS/GS (from 43  2 to 53  3 vs. 38  2 to 66  3
GS [7] show decreased stimulated intracellular Ca2pmol/min/mg protein, P  0.05 for the difference). Membrane
PKC expression was similar in basal conditions (8.5  1.5 vs. release [8] and inositol-1,4,5,trisphosphate production
12.4  4.0 densitometric units), but increased after fMLP was (IP3) in neutrophils [9], which point toward a reduced
reduced in BS/GS (4.5 1.4 vs. 9.5  2.1, P 0.01). In BS/GS, protein kinase C (PKC) activity and cell reactivity.PKC stimulation with PMA dose dependently reduced ecNOS
Protein kinase C is a serine threonine-specific kinasegene expression (from 0.80  0.05 to 0.78  0.03 densitometric
that plays a key role in a wide range of signal transductionunits; PMA 50 nmol/L, P  NS; to 0.55  0.07, PMA 100
processes [10], among which is the regulation of the
constitutive endothelial isoform of nitric oxide synthase
1 See Editorial by Warnock, p. 1197 (ecNOS) [11]. In particular, PKC activation inhibits
ecNOS mRNA and NO production, while the oppositeKey words: G protein, signal transduction, vascular tone, nitric oxide,
endothelial isoform of NOS. happens with PKC inhibition [11]. This may account for
our previous observations such as increased urinary
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duced susceptibility of low-density lipoprotein to oxida- Pi, 0.5 mmol/L CaCl2, 5.6 mmol/L glucose, and 20 mmol/L
HEPES (pH 7.4 at 37C) as previously reported [8].tion secondary to NO overproduction [15] in patients
Neutrophils from patients and controls were preincu-with BS and GS.
bated for 10 minutes at 37C with fMLP at a concentra-The whole of these findings points to a generalized
tion of 3 107 mol/L, which is critical for the demonstra-abnormality of cell signaling in BS and GS. Therefore,
tion of reduced fMLP-stimulated intracellular calciumaim of the present study was to evaluate the relationship
release [8, 9]. After 10 minutes, the incubation was stoppedbetween membrane PKC activation and ecNOS gene
by centrifugation at 4C at 1200 rpm  20 minutes. Theexpression in circulating nucleated blood cell from pa-
supernatant was discarded, and the pellet was immedi-tients with BS and GS. In addition, we investigated the
ately lysed with ice-cold extraction buffer containing 12.5expression of the  subunit of the Gq heterotrimeric gua-
mmol/L Tris-HCl (pH 7.4), 250 mmol/L sucrose, 2 mmol/Lnine nucleotide-binding regulatory protein, which trans-
ethylenediaminetetraacetic acid (EDTA), 2 mmol/L eg-duces the signal to a phospholipase C-	 [16] to generate
tazic acid (EGTA), 25 mmol/L B-glycerophosphate, 2IP3 and to release Ca2 from the intracellular stores.
mmol/L sodium vanadate, 10 
mol/L phenylmethylsul-
fonyl fluoride (PMSF), 1
g/mL leupeptin, 5
g/mL aprot-
METHODS inin. Cells were disrupted with a Dounce homogenizer
(20 strokes) on ice for one minute. The homogenate wasStudy groups
centrifuged at 800  g for 10 minutes at 4C to removeNine patients (6 males and 3 females, 24 to 50 years
cell debris and nuclei. The homogenate was then centri-old), with either BS (N 2) or GS (N 7) were studied.
fuged at 100,000  g for one hour at 4C in a BeckmanThey were divided into “pure” Bartter and the Gitelman
centrifuge (TI 50). The supernatant (cytosolic fraction)variant, according with the biochemical criteria suggested
was removed and stored at 80C. The pellet (mem-by Bettinelli et al [17] as previously reported [13].
brane fraction) was resuspended in extraction bufferTen healthy controls (6 males and 4 females, age range
with 1% Triton X-100 and incubated with continuous23 to 47 years) were recruited from the staff of the De-
shaking at 4C for one hour. The membrane fraction waspartment of Clinical and Experimental Medicine at the
centrifuged at 100,000  g for 30 minutes at 4C, andUniversity of Padova.
the supernatant (containing membrane PKC) was stored
at 80C. The protein concentration was determinedMutation detection studies
with Bio-Rad DC assay (Bio-Rad, Hercules, CA, USA)These studies were performed at the Department of
using bovine serum albumin (BSA) as the standard.Pediatric Nephrology, Academic Hospital Nijmegen, The
Ca2 and phospholipid-dependent PKC activity was
Netherlands. measured as previously described [20]. Briefly, phos-
Patients’ genomic DNA was extracted by a salting- phorylation reactions were performed in the mixture con-
out procedure from peripheral blood lymphocytes and taining (final volume 175 
L) 12 mmol/L calcium acetate,
used for polymerase chain reaction (PCR) amplification 30 mmol/L dithiothreitol, 50 mmol/L Tris-HCl, 900
mol/L
of the individual exons of the SLC12A3 gene, also known substrate peptide (R-K-R-T-L-R-R-L), a detergent-dis-
as NCCT [18, 19]. Twenty-six pairs of oligonucleotide persed solution of 400 
mol/L L-phosphatidyl-L-serine
primers were generated to amplify all 26 exons according (Pser) and diacylglycerol (DAG), and [-32P] ATP. In the
to established procedures. Also, mutation detection in assays, PKC activity also was measured in the absence of
the ROMK gene in Bartter’s patients was performed on Ca2 (that is, in the presence of EGTA) and phospholip-
genomic DNA level by a combination of PCR and DNA ids. The reaction was initiated by adding 25 
L of the
sequence analyses. cytosolic fractions or membranes (30 
g of protein).
Each of the SLC12A3 or ROMK exons were subjected After 15 minutes of incubation at 25C, the reaction
to double-stranded DNA sequencing in the presence of was stopped with trichloroacetic acid. An aliquot of the
dye-dideoxy terminators [18, 19]. Reaction conditions reaction media was spotted on a phosphocellulose paper.
were performed according to protocols supplied by the The paper was washed with 5% vol/vol acetic acid and
manufacturer (Perkin-Elmer-ABI, Foster City, CA, USA) assayed for 32P by scintillation counting. PKC activity
and analyzed on an ABI 377 automated DNA sequencer was expressed as picomoles of 32P incorporated into
(Perkin-Elmer-ABI). peptide/mg of protein/min (pmol  mg protein1 
min1), calculated in the presence of Ca2/phospholipid
Determination of PKC activity in neutrophils minus the activity obtained in the absence of Ca2, Pser,
Neutrophils, more than 98% pure, were prepared by and DAG.
dextran sedimentation and centrifugation on Ficoll Hy-
Immunoblot analysis of PKC in monocytespaque gradients. After hypo-osmotic lysis of contaminat-
ing erythrocytes, the cells were suspended in medium Peripheral blood monocytes from 35 mL of EDTA anti-
coagulated blood were isolated by the NycoPrep gradientcontaining 138 mmol/L NaCl, 6 mmol/L KCl, 1 mmol/L
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method essentially as detailed by the manufacturer (Nyco- containing RNA and DNAse was extracted with phenol:
chloroform:isoamylic alcohol (25:24:1 vol:vol:vol) andMed Pharma, Asker, Norway) and judged to be 85%
pure and functionally alive by cytoflurometric analysis. centrifuged at 12,000  g for two minutes. The RNA
containing supernatant was mixed with an equal amountCells at a concentration of 1  106 mL were placed in
culture plates with RPMI 1640 supplemented with 2% of chlorophorm:isoamylic alcohol (24:1 vol:vol). The
aqueous phase was precipitated with 1:10 vol/vol Nafetal calf serum. Cells from Bartter and Gitelman pa-
tients were incubated for 15 minutes in the presence and acetate 3.25 mol/L and 2 vol/vol 100% ethanol and stored
at80C for 30 minutes. The suspension was then centri-absence of the PKC activator PMA (50, 100, and 200
nmol/L), while cells from controls for 15 minutes in the fuged at 12,000  g for five minutes, and the pellet was
washed with 70% ethanol. The pellet, containing RNApresence and absence of the specific PKC inhibitor bisin-
dolylmaleimide, GF109203X (GFX; 1.2 
mol/L) [21]. purified from contaminating genomic DNA, was resus-
pended in DEPC water ready to be used for reverseBoth PMA and bisindolylmaleimide were dissolved in
dimethyl sulfoxide. These stock solutions were then di- transcription.
Reverse transcription of the RNA was performed withluted with RPMI 1640, pH 7.4, and directly added to the
medium. the Gene Amp RNA PCR Kit, essentially as described
by the manufacturer (Gene Amp RNA PCR Kit; Perkin-Immunoblot analysis of PKC was performed as pre-
viously reported [22]. In brief, cytosolic and membrane Elmer). RNA (1 
g) was reverse transcribed using
random hexamer primers, MuLV reverse transcriptasefraction from human monocytes were probed with rabbit
polyclonal antibodies for PKC (Santa Cruz Biotechnol- in a Perkin Elmer 2400 thermacycler (15 minutes at 42C,
5 minutes at 99C, and 5 minutes at 5C).ogy, Santa Cruz, CA, USA). Cytosolic and membrane
protein extracts (30
g) were solubilized in Laemmli buffer Polymerase chain reaction amplification of the cDNA
was done essentially as described in the kit. The oligomerand then separated by electrophoresis through a 10% poly-
acrylamide gel. Proteins separated on the gels were elec- primers used for ecNOS gene expression were 5-ACAT
GTTTGTCTGCGGCG-3 and 5-GCARGGAAAAGtroblotted onto Hybond ECL nitrocellulose membrane
(Amersham, Pharmacia, Piscataway, NJ, USA) in Tris- CTCTGGGT-3 [13, 24]. The reaction mixture contained
20 
L cDNA, 0.15 mmol/L of sense and antisense prim-glycine transfer buffer with 20% methanol for two hours
at 100 V in the cold, using a Transblot cell (Elettrofor, ers, 2.5 U Taq DNA polymerase (Perkin-Elmer), and
0.056 mmol/L Anti Taq Polymerase (Clontech, PaloPadova, Italy). Blocking of the nitrocellulose membranes
was performed under overnight agitation at 4C in phos- Alto, CA, USA) in a final volume of 100 
L.
The conditions of amplification were set to denaturephate-buffered saline (PBS) containing 0.05% (vol/vol)
PBST and 5% BSA. Membranes were exposed to pri- at 94C for one minute, to anneal at 58C for one minute,
and to extend at 72C for one minute, for a total of 35mary antibody (anti-PKC 1:2000) overnight at 4C. Mem-
branes were washed (4  20 min) with the same buffer cycles of amplification as previously reported [24].
The oligos used for the  subunit of Gq gene expres-and then incubated with horseradish peroxidase-conju-
gated, 1:4000 goat anti-rabbit antibody. Detection was sion were obtained using the Primer3 software [25]:
5-GAGCACAATAAGGCTCATGCAC-3 (307 to 329)made using the enhanced chemiluminescence system
(ECL) from Amersham. Blots were scanned and quanti- and 5-TGTACTCCTTCAGGTTCAACTG-3 (1046 to
1068).fied with a Bio-Rad Chemiluminescence Molecular Im-
aging System, and the results were expressed as the ratio The reaction mixture contained 20 
L cDNA, 2.5 U
Taq DNA polymerase (Perkin-Elmer), 0.8
mol/L sense,to a control, on the same blot, set at 100%.
and antisense primer, in a final volume of 100 
L. After
Determination of ecNOS and Gq mRNA an initial denaturation at 94C five minutes, the condi-
production in monocytes tions of amplification were set to denature at 94C for
one minute, to anneal at 50C for 50 seconds, to extendAfter 15 minutes of incubation with the experimental
reagents, RNA from PBM was extracted using a com- at 72C for one minute and 50 seconds, for a total of 35
cycles of amplification with a final extension at 72C mercially available kit (UltraSpec RNA isolation system;
Biotecx, Houston, TX, USA) with l mL of product per ten minutes.
	-Actin (for ecNOS PCR) and GAPDH (for Gq5  106 cells. The isolated RNA had an OD of 280:260
ratio between 1.8 and 2.0. PCR) were used as control and amplified using commer-
cially available primers for 	-actin (Clontech) and theOne microgram of extracted RNA was incubated at
37C for 15 minutes with RQ1 RNase free DNase (Pro- following GAPDH primers: 5-ACCACAGTCCATGC
CATCAC-3 (586 to 605), and 5-TCCACCACCCTGTmega, Madison, WI, USA) to avoid the inadvertent am-
plification of the described processed pseudogene that TGCTGTA-3 (1018 to 1037). PCR products were sepa-
rated by electrophoresis on polyacrylamide gel and stainedhas an extraordinarily high nucleotide sequence identity
with the authentic human Gq cDNA [23]. The mixture by silver staining. A molecular weight marker, IX (X174
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Table 1. SLC12A3 mutations identified in the patients with
Gitelman syndrome
Mutation at Homo- Predicted effect
Patient Exon nucleotide heterozygous on protein
1 23 2736G→A heterozygous Arg904Gln
2 22 2579C→T heterozygous Arg852Cys
23 2736G→A heterozygous Arg904Gln
3 23 2736G→A heterozygous Arg904Gln





18 2246G→A heterozygous Gly741Arg
5 22 2579C→T heterozygous Arg852Cys
23 2736G→A homozygous Arg904Gln
6 22 2579C→T heterozygous Arg852Cys
23 2736G→A heterozygous Arg904Gln
7 23 2735G→A homozygous Arg904Gln
Fig. 1. Basal and fMLP (3 107 mol/L)-stimulated membrane proteinHaeIII; Boehringer-Mannheim, Mannheim, Germany), kinase C (PKC) activity in neutrophils from patients with Bartter syn-
was included in the gel. drome (BS) and Gitelman syndrome (GS), and from healthy controls.
*P  0.05; **P  0.01. BS/GS, Bartter and Gitelman patients.A control PCR with RNA not subjected to reverse
transcription also was performed to exclude the possibil-
ity of genomic DNA contamination.
Nucleotide sequence determination for both ecNOS PCR in combination with automatic DNA sequencing of
and Gq was performed at Primm s.r.l. (San Raffaele 26 exons that encode the complete coding region. As shown
Biomedical Science Park, Milano, Italy) using the PRISM in Table 1, 11 mutations have been identified consisting of
Taq Polymerase Dye Terminator fluorescent sequencing six mutations 2736G→A, two homozygous and four het-
kit (Perkin-Elmer), and analyzed using an ABI 373 auto- erozygous, with a predicted effect on protein Arg904Gln;
mated sequencer and ABI Prism analysis software. three mutations 2579C→T, heterozygous, with a predicted
The ecNOS and Gq gene products from patients and effect on protein Arg852Cys; one mutation 1950G→A,
controls were quantitated by a PCR-based semiquantita- heterozygous, with a predicted effect on protein Arg642His
tive analysis of ecNOS and Gq mRNA expression. or splice donor site-truncated SMLC12A3 protein; and
ecNOS and Gq RNAs were compared with the expres- one mutation 2246G→A, heterozygous, with a predicted
sion of a defined control gene, 	-actin, and GAPDH, effect on protein Gly741Arg. None of the Bartter pa-
respectively. The intensity of the PCR products was tients had a mutation present in the ROMK gene. Human
quantitated by pixel density using NIH-Image. The ratios genomic DNA is still under evaluation, and the results
ecNOS/	-actin and Gq/GAPDH were used as index of for mutations in the candidate genes are still pending.
ecNOS and Gq gene expressions. For each experiment, These patients, however, fulfilled the biochemical crite-
the ratios of ecNOS and Gq mRNA to the correspond- ria suggested by Bettinelli et al to be classified as “pure”
ing 	-actin and GAPDH mRNA were calculated and BS, as previously reported [13, 17].
densitometrically quantitated by pixel density using NIH
image software. PKC assay and immunoblot analysis of
PKC isoenzymeStatistical analysis
Cytosol and membrane basal PKC activity were notData were evaluated on a Power Macintosh 5400/180
significantly different in neutrophils from BS and GScomputer (Apple Computer, Cupertino, CA, USA) us-
patients and controls: 70 3 in BS/GS patients and 80ing the Statview II statistical package (BrainPower Inc.,
2 pmol/min/mg protein in controls, in the cytosol; 43.2 Calabasas, CA, USA). Data are expressed as mean 
2 in BS/GS patients and 38  2 pmol/min/mg protein inSD, and they were analyzed using the Student t test for
controls in the membranes.unpaired data. Values at a 5% level or less (P  0.05)
The addition of fMLP to the cells increased membranewere considered significant.
PKC activity, but the increase was significantly lower
(P  0.01) in BS/GS patients compared with controls
RESULTS (from 43  2 to 53  3 pmol/min/mg protein in BS/GS
patients and from 38  2 to 66  3 pmol/min/mg proteinHuman genomic DNA from seven GS patients have
been screened for mutations in the SLC12A3 gene by in controls; Fig. 1).
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Fig. 2. Representative immunoblot of the
PKC isoform in the membrane fraction of
monocytes from one patient (P) and one control
(C) subject in the presence and in the absence
of fMLP (3  107 mol/L; A). (B and C ) The
densitometric analysis of PKC at baseline
and after fMLP in controls and BS/GS patients
is shown. There was no significant difference
between the two groups at baseline, but the
increase after fMPL was blunted in BS/GS
patients in comparison to controls (P  0.01,
right lower panel). Abbreviations are: fMLP,
formylmethionyl-leucyl-phenylalanina. Other
abbreviations are in the legend to Figure 1.
Figure 2 shows a representative immunoblot of the
PKC isoform in the membrane fraction of monocytes
from one patient and one normal subject (Fig. 2A) and
the mean densitometric analysis of the two study groups
(Fig. 2B, C). In basal conditions, there was no difference
in the BS/GS patients compared with normal subjects:
8.5  1.5 vs. 12.4  4.0 densitometric units (Fig. 2B).
However, its increase after fMLP was significantly re-
Fig. 3. Representative experiments of an endothelial isoform of nitricduced in BS/GS patients compared with control subjects oxide synthase (ecNOS) gene expression in monocytes at baseline and
(4.5  1.4 vs. 9.5  2.1, P  0.01; Fig. 2C). after exposure to the PKC stimulator PMA at the indicated concentra-
tions. (A) PMA dose-dependently reduces ecNOS gene expression in
a patient with BS. (B) Comparison of one control subject and one BSEffect of modulation PKC activity on ecNOS
patient. At baseline, ecNOS gene expression is higher in the patientgene expression than in the control subject, and PMA reduces ecNOS gene expression
to the same extent in the patient and in the control subject. AbbreviationThe effect of the PKC activator PMA on ecNOS gene
is: Mwm, DNA molecular weight marker IX (X174 Hae III). Theexpression was investigated in monocytes (Fig. 3). PMA other abbreviations are as in Figure 1.
(50, 100, and 200 nmol/L) dose-dependently reduced
ecNOS gene expression in monocytes of BS and GS
patients: from 0.80  0.05 to 0.78  0.03 d.u. (at
50 nmol/L, P  NS), to 0.55  0.07 (at 100 nmol/L P  Gq gene expression
0.001), to an undetectable expression at 200 nmol/L. Figure 5 shows representative assays for Gq gene
Figure 3A shows one representative experiment. The
expression, assessed by RT-PCR oligonucleotide ampli-effect of PMA was qualitatively similar in controls sub-
fication, from patients with BS (lane 5) and GS (lane 6jects (Fig. 3B).
and 7) and from controls (lanes 2, 3, and 4). The identityIn contrast, the incubation of monocytes from control
of the amplified product was confirmed by sequencingsubjects with the selective PKC inhibitor GF109203X
the PCR fragment. It resulted in a 761 bp long fragment(1.2 
mol/L) increased ecNOS mRNA from 0.41  0.04
with 100% identity to the reported functional “authen-to 0.62 0.05, d.u. (P0.001). Figure 4 compares the effect
tic” human Gq isoform gene sequence [23].of GF109203X in monocytes from one control subject and
The level of Gq gene expression, evaluated by theone BS/GS patient, and shows that GF109203X increases
ratio of Gq PCR product to GAPDH PCR product,ecNOS gene expression to the same extent in the patient
was significantly decreased in BS and GS patients inand in the control. Furthermore, the experiments shown
comparison with controls (0.87  0.013 vs. 0.98  0.005in Figures 3 and 4 confirm that at baseline, ecNOS gene
expression is higher in patients than in controls [13]. densitometric units, P  0.0004).
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Fig. 5. Representative assay for Gq RT-PCR amplified oligonucleo-
tides from patients with BS (lane 5) and GS (lanes 6 and 7) and from
controls (lanes 2, 3, and 4). The DNA molecular weight marker IX
(X174 HaeIII) is reported in lane 1. It can be seen that the level of
Gq gene expression is decreased in the patients in comparison withFig. 4. ecNOS gene expression at baseline and after exposure to PKC
the control subjects.inhibitor GF109203X (1.2 mol/L) in monocytes from one control
subject and from one GS patient. The PKC inhibitor GF109203X in-
creases ecNOS gene expression in the patient and in the control subject
to the same magnitude. GFX is GF109203X; the other abbreviations neutrophils. The agonist-induced increase of membrane
are the same as in Figure 2. PKC is half of controls and of the same magnitude of
the reduction of fMLP-stimulated intracellular Ca2 and
IP3 release shown in previous studies [8, 9].DISCUSSION
A generalized reduction of PKC activity could account
The present study conducted in two different cell types for the increased ecNOS gene expression, previously
(neutrophils and monocytes) suggests an abnormal Gq- shown in monocytes [13]. In fact, the incubation of pa-
mediated cell signaling in patients with BS/GS. It shows tients’ monocytes with the PKC activator PMA strongly
reduced Gq gene expression and membrane PKC activa- and dose-dependently reduced ecNOS gene expression.
tion and increased ecNOS gene expression. These findings, In contrast, parallel experiments with monocytes from
therefore, extend our previous observations showing that healthy subjects incubated with GFX, a potent and selec-
there is abnormal cell signaling in BS and GS patients tive inhibitor of PKC, showed a strong stimulation of
[8, 9], activation of NO system with increased ecNOS ecNOS gene expression.
gene expression [13], and increased urinary NO2 /NO3 Evidence of PKC-dependent regulation of ecNOS
and cGMP excretion [12]. It also provides an experimental gene expression suggests that the up-regulation of NO
explanation for the vascular abnormalities of the patients system is not a primary feature of BS and GS, but could
with BS/GS, namely hypotension, hyporesponsiveness be a consequence of the abnormal intracellular cell sig-
to vasoconstrictors, and resistance to atherosclerosis [15]. naling leading to reduced PKC activity and reduced in-
Our earlier investigations in BS/GS patients found a tracellular IP3 and Ca2 production [8, 9], all of them
reduced intracellular IP3 and Ca2 release [8, 9]. These contributing to reduced vascular reactivity [26].
results suggested a defect in the intracellular calcium- The location of the defect along the intracellular cal-
mediated signaling system as a contributor to the vascu- cium signaling could be upstream, at the level of the
lar hyporeactivity of BS/GS. This was further supported receptor coupling with the polyphosphoinostide-specific
by more recent studies in the same patients showing phospholipase C (PLC), via the G protein [9, 27]. Activa-
activation of NO system (increased ecNOS gene expres- tion of the renin-angiotensin system and reduced respon-
sion [13], increased urinary NO2 /NO3 and cGMP excre- siveness to exogenous Ang II in patients with BS/GS
tion [12]), NO-related reduced vascular tone [14], and points to abnormal Ang II-mediated cell signaling. How-
susceptibility of low-density lipoprotein to oxidation [15]. ever, the Ang II receptor density is normal, and no muta-
It has been reported that PKC is a major regulator of tion in AT1 receptors has been reported consistently in
ecNOS [11], and shown that activation of PKC by phor- these patients [28].
bol esters inhibits the endothelium-dependent vasodila- The stimulation of Ang II activates two G proteins
tory responses, while PKC inhibition increases ecNOS of the Gq family, Gq and G11, leading to an increased
gene expression and NO production [11]. In BS/GS, the cytoplasmic Ca concentration [16]. Only the  subunit
altered intracellular calcium signaling system suggested of the Gq protein transduces the signal to PLC-	 to
reduced PKC activation [9]. This was addressed in the generate IP3 and DAG [16]. Therefore, we assessed
present study in neutrophils, since previous studies mRNA expression of the  subunit of the Gq protein
showed that fMLP, an activator of Ca2-dependent PKC in monocytes of BS/GS patients and showed that it is
isoform, elicited a depressed Ca2 response in this type significantly reduced. The same phenomenon in vascular
of cells from BS/GS patients [8, 9]. The present study smooth muscle cells may reduce vascular reactivity and
cause hypotension. This suggestion is further strength-confirms reduced membrane fMLP-stimulated PKC in
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ened by the evidence of defective platelet activation in APPENDIX
Gq knockout mice [29]. Abbreviations used in this article are: ATP, adenosine 5-triphos-
phate; BS, Bartter syndrome; [Ca2]i, intracellular calcium; DAG, diac-The mechanism(s) responsible for the reduced Gq
ylglycerol; ecNOS, endothelial isoform of nitric oxide synthase; EDTA,mRNA level (reduced synthesis or increased degrada-
ethylenediaminetetraacetic acid; fMLP, formylmethionyl-leucyl-phe-
tion) remains unidentified. Hereditary and acquired de- nylalanina; Gq, alpha subunit of the Gq heterotrimeric guanine nucle-
otide-binding regulatory protein; GFX, GF109203X; GS, Gitelmanfects that alter the intracellular signaling system and,
syndrome; IP3, inositol-1,4,5,triphosphate; LDL, low density lipopoly-in particular, the transducing components, such as the saccharide; NO, nitric oxide; NOS, nitric oxide synthase; PKC, protein
G-protein complex, have been described [30]. An altered kinase C; PMA, phorbol 12-myristate 13-acetate; PMSF, phenylmethyl-
sulfonyl fluoride; Pser, L-phosphatidy-L-serine; RT-PCR, reverse tran-regulation of the Gq mRNA seems likely, since the
scribed-polymerase chain reaction.
analysis of the Gq gene products from our patients
resulted identical to that of controls and to that of the REFERENCES
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